Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Archives of Oto-Rhino-Laryngology
Published in: European Archives of Oto-Rhino-Laryngology 12/2019

01-12-2019 | Dexamethasone | Otology

Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study

Authors: Gökçe Simsek, Burak Mustafa Taş, Nuray Bayar Muluk, Musa Azman, Rahmi Kılıç

Published in: European Archives of Oto-Rhino-Laryngology | Issue 12/2019

Login to get access

Abstract

Purpose

The main aim of this study was to compare the efficacy of intratympanic administration of dexamethasone and resveratrol in preventing cisplatin ototoxicity by measuring acoustic brainstem response (ABR) and distortion product otoacoustic emission (DPOAE).

Methods

Forty rats (80 ears) were divided into five groups. Cisplatin was administered intraperitoneally to the first group (n = 8). Group 2 (n = 8) received cisplatin after resveratrol had been administered intratympanically. Group 3 (n = 8) received cisplatin after dexamethasone had been administered intratympanically. Group 4 (n = 8) received cisplatin after sodium chloride (NaCl) had been given intratympanically. Group 5 (n = 8) received cisplatin after dimethylsulfoxide (DMSO) had been given intratympanically. ABR and DPOAE tests were performed on all groups before and 72 h after the procedure.

Results

ABR threshold values in rats that received dexamethasone and resveratrol were found to be less affected than those observed in the other post-cisplatin groups. ABR-IV and ABR-I–IV interval values were significantly reduced in rats that had been given dexamethasone and resveratrol compared to the other groups. After cisplatin treatment, otoacoustic emission (OAE) amplitudes were significantly decreased in Groups 1, 4, and 5 for all frequencies, while OAE values were sustained in the resveratrol and dexamethasone groups (Groups 2 and 3). At OAE frequency 5652, dexamethasone was more significantly associated with protective than resveratrol was, while no significant difference was found between the two groups at other OAE frequencies.

Conclusion

In conclusion, intratympanic dexamethasone and intratympanic resveratrol treatments may provide a significant protection against cisplatin-induced ototoxicity.
Literature
1.
Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP (2018) Ototoxicity: a challenge in diagnosis and treatment. J Audiol Otol 22(2):59–68CrossRef
2.
Campbell KCM, Le Prell CG (2018) Drug-induced ototoxicity: diagnosis and monitoring. Drug Saf 41(5):451–464CrossRef
3.
Liu W, Staecker H, Stupak H, Malgrange B, Lefebvre P, Van De Water TR (1998) Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells. NeuroReport 9:2609–2614CrossRef
4.
McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228–244CrossRef
5.
Liang F, Schulte BA, Qu C, Hu W, Shen Z (2005) Inhibition of the calcium and voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. Neuroscience 135:263–271CrossRef
6.
Doyle KJ, Bauch C, Battista R et al (2004) Intratympanic steroid treatment: a review. Otol Neurotol 25:1034–1039CrossRef
7.
Simşek G, Tokgoz SA, Vuralkan E, Caliskan M, Besalti O, Akin I (2013) Protective effects of resveratrol on cisplatin-dependent inner-ear damage in rats. Eur Arch Otorhinolaryngol 270(6):1789–1793CrossRef
8.
Yumusakhuylu AC, Yazici M, Sari M, Binnetoglu A, Kosemihal E et al (2012) Protective role of resveratrol against cisplatin induced ototoxicity in guinea pigs. Int J Pediatr Otorhinolaryngol 76(3):404–408CrossRef
9.
Lee SH, Kim HS, An YS, Chang J, Choi J, Im GJ (2015) Protective effect of resveratrol against cisplatin-induced ototoxicity in HEI-OC1 auditory cells. Int J Pediatr Otorhinolaryngol 79(1):58–62CrossRef
10.
Dinh CT, Chen S, Dinh J, Goncalves S, Bas E et al (2017) Effects of intratympanic dexamethasone on high-dose radiation ototoxicity in vivo. Otol Neurotol 38(2):180–186CrossRef
11.
Seligmann H, Podoshin L, Ben-David J, Fradis M, Goldsher M (1996) Drug-induced tinnitus and other hearing disorders. Drug Saf 14:198–212 (review) CrossRef
12.
13.
Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ et al (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77:1355–1362CrossRef
14.
Huang E, Teh BS, Strother DR et al (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 1(52):599–605CrossRef
15.
Reavis KM, McMillan GP, Dille MF, Konrad-Martin D (2015) Meta-analysis of distortion product otoacoustic emission retest variability for serial monitoring of cochlear function in adults. Ear Heart 36(5):e251–e260CrossRef
16.
Martín-Saldaña S, Palao-Suay R, Trinidad A, Aguilar MR, Ramírez-Camacho R et al (2016) Otoprotective properties of 6α-methylprednisolone-loaded nanoparticles against cisplatin: in vitro and in vivo correlation. Nanomedicine 12:965–976CrossRef
17.
Hargunani CA, Kempton JB, DeGagne JM, Trune DR (2006) Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. Otol Neurotol 27:564–569PubMed
18.
Palmer RM, Bridge L, Foxwell NA et al (1992) The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br J Pharmacol 105:11–12CrossRef
19.
Kiliç R, Safak MA, Oğuz H, Kargin S, Demirci M et al (2007) Intratympanic methylprednisolone for sudden sensorineural hearing loss. Otol Neurotol 3:312–316
20.
Han X, Yin X, Du X, Sun C (2017) Combined intratympanic and systemic use of steroids as a first-line treatment for sudden sensorineural hearing loss: a meta-analysis of randomized. Control Trials Otol Neurotol 38(4):487–495CrossRef
21.
22.
Hill GW, Morest DK, Parham K (2008) Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. Otol Neurotol 29(7):1005–1011CrossRef
23.
Marshak T, Steiner M, Kaminer M, Levy L, Shupak A (2014) Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a randomized controlled study. Otolaryngol Head Neck Surg 150(6):983–990CrossRef
24.
Vidavalur R, Otani H, Singal PK, Maulik N (2006) Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol 11(3):217–225PubMedPubMedCentral
25.
26.
Yan Y, Yang J, Chen G, Mou Y, Zhao Y, Pan L, Ma C, Liu X, Wu C (2011) Protection of resveratrol and its analogues against ethanol-induced oxidative DNA damage in human peripheral lymphocytes. Mutat Res 721(2):171–177CrossRef
27.
Avcı D, Erkan M, Sönmez MF, Kökoğlu K, Güneş MS et al (2016) A prospective experimental study on the protective effect of resveratrol against amikacin-induced ototoxicity in rats. J Int Adv Otol 12(3):290–297CrossRef
28.
Erdem T, Bayindir T, Filiz A, Iraz M, Selimoglu E (2012) The effect of resveratrol on the prevention of cisplatin ototoxicity. Eur Arch Otorhinolaryngol 269(10):2185–2188CrossRef
29.
Metadata
Title
Comparison of the protective efficacy between intratympanic dexamethasone and resveratrol treatments against cisplatin-induced ototoxicity: an experimental study
Authors
Gökçe Simsek
Burak Mustafa Taş
Nuray Bayar Muluk
Musa Azman
Rahmi Kılıç
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Keyword
Dexamethasone
Published in
European Archives of Oto-Rhino-Laryngology / Issue 12/2019
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-019-05635-x

Other articles of this Issue 12/2019

European Archives of Oto-Rhino-Laryngology 12/2019 Go to the issue

Head and Neck

Ex-vivo surgical model for “Barbed Snore Surgery”: a feasibility study

Head and Neck

Morphometric examination of the styloid process by 3D-CT in patients with Eagle syndrome

Head and Neck

Anterolateral thigh free flap in reconstruction of lateral skull base defects after oncological resection

Laryngology

Transglottic corticosteroid injection for treatment of soft post-intubation subglottic stenosis: a retrospective analysis of 26 children

Rhinology

The association of allergic rhinitis severity with neutrophil–lymphocyte and platelet–lymphocyte ratio in adults

Letter to the Editor

In response to the ‘Letter to the Editor’ on the paper ‘Aging effect on sleepiness and apneas severity in patients with obstructive sleep apnea syndrome: a meta-analysis study’